Growth Metrics

Eli Lilly (LLY) Gains from Investment Securities (2016 - 2026)

Eli Lilly filings provide 18 years of Gains from Investment Securities readings, the most recent being $297.0 million for Q1 2026.

  • On a quarterly basis, Gains from Investment Securities rose 367.57% to $297.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.1 billion, a 134.57% increase, with the full-year FY2025 number at $645.0 million, down 4.73% from a year prior.
  • Gains from Investment Securities hit $297.0 million in Q1 2026 for Eli Lilly, down from $589.2 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $971.9 million in Q3 2023 to a low of -$456.8 million in Q2 2023.
  • Median Gains from Investment Securities over the past 5 years was $151.9 million (2024), compared with a mean of $173.5 million.
  • Biggest five-year swings in Gains from Investment Securities: soared 509.13% in 2022 and later plummeted 1966.97% in 2023.
  • Eli Lilly's Gains from Investment Securities stood at $266.1 million in 2022, then decreased by 3.72% to $256.2 million in 2023, then crashed by 40.71% to $151.9 million in 2024, then surged by 287.89% to $589.2 million in 2025, then tumbled by 49.59% to $297.0 million in 2026.
  • The last three reported values for Gains from Investment Securities were $297.0 million (Q1 2026), $589.2 million (Q4 2025), and -$312.1 million (Q3 2025) per Business Quant data.